Investment analysts at Leerink Partners began coverage on shares of Parabilis Medicines (NASDAQ:PBLS – Get Free Report) in a note issued to investors on Monday,Benzinga reports. The brokerage set an “outperform” rating and a $40.00 price target on the stock. Leerink Partners’ target price indicates a potential upside of 35.23% from the company’s current price.
Several other research analysts have also recently issued reports on the stock. Guggenheim assumed coverage on shares of Parabilis Medicines in a report on Monday. They set a “buy” rating and a $40.00 price target for the company. Wall Street Zen upgraded Parabilis Medicines to a “hold” rating in a research report on Saturday, June 20th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $41.67.
Check Out Our Latest Report on PBLS
Parabilis Medicines Stock Performance
Insider Transactions at Parabilis Medicines
In related news, Director Alan Sebulsky acquired 12,500 shares of Parabilis Medicines stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the purchase, the director directly owned 12,500 shares of the company’s stock, valued at approximately $250,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Guy Levy acquired 500,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average cost of $20.00 per share, for a total transaction of $10,000,000.00. Following the acquisition, the insider owned 1,027,000 shares of the company’s stock, valued at $20,540,000. This represents a 94.88% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 530,000 shares of company stock valued at $10,723,528 in the last quarter.
Featured Articles
- Five stocks we like better than Parabilis Medicines
- Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks
- Visa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure
- This Under-the-Radar Industrial Is Quietly Powering AI
- Why Microsoft Looks Like the Best Big Tech Trade for H2 2026
Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
